HAIR, too late? We might get another chance!This started to take off mid day today.
I already have two positions but looking for a third on a pullback.
My first entry was near the low of October 15th which was a test of the bull trend line.
Got a second entry near the low of October 16th which also tested the bull trend line and made higher lows from the day before.
Looking for a third entry on or near a retest of the close from October 16th, identified by the box on the chart.
It might not make it there because we've established a pretty good battle ground, as seen by the heavy volume profile near $2.15.
Ideal profit target would be along the first trend line, with a possible reentry if the trend line gets broken. We will see when that time comes.
As always, practice safe risk management!
HAIR
Hair Jump inThe shares of the corporation went up by 22.85% during the previous month. So far this year, the stock had gone up by 8.7%. With these types of results to display analysts, are more optimistic than before! Analyzing the last five market sessions, the stock was able to report 15.47% gains.Clarus Ventures LLC bought a new stake in shares of Restoration Robotics during the fourth quarter.HAIR has been the topic of several other reports and Roth Capital set a $7.50 price objective on shares of Restoration Robotics with a BUY rating in a recent research note.
100,00% ROI REPCF Hair CloningWithout a product Replicel reached $300 during it's bubble. It's Japanese partner Shiseido still angry in a frosty relationship with Replicel due to lack of delayed funding on REPCF's german trial - is now rumored to make an announcement 2018 using REPCF's IP. Shiseido and Replicel were involved in a deal years ago that concluded Shiseido owns the human population of Asia in regards to marketing and collecting royalties off this hair cloning technology in trade that both companies spend tens of millions of dollars on research and human trials. When Replicel failed to spend Shiseido threatened to sue. Now that the situation has settled the science remains to be showcased. Because it's already been tested. Human trials have been conducted the last 2 years. The company Shiseido is sitting on that data. Whether they are sitting on the biggest cosmetic market on the planet or not is in that data.
At a quick glance you can see the timeline and the run up in price. This technology has a head start in japan being autologous there is NO third phase clinical trial only phase 2.
Excellent long. 100,000 ROI set up. ($1,000 to $1,000,000) if this thing hits it's previous resistance from 12 years ago.
Long COOL Burn victims and skin regeneration from PolarityTE will be the first time in human history a medical application of organ cloning will be applied to patient's.
If they prove successful then they will be moving into other derivative products according to their team including androgenic alopecia.
There is a great article from seeking alpha claiming they could be a corrupt company for the perfect short.
The product being released first 6 months of next year will dictate whether this company is a buy.
